Kiora Pharmaceuticals (NASDAQ:KPRX) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Kiora Pharmaceuticals (NASDAQ:KPRX) in a report published on Friday morning,Benzinga reports. They currently have a $10.00 price target on the stock.

Kiora Pharmaceuticals Trading Up 2.0 %

KPRX opened at $3.08 on Friday. Kiora Pharmaceuticals has a 12 month low of $2.91 and a 12 month high of $6.30. The company has a market cap of $9.24 million, a PE ratio of 2.96 and a beta of -0.46. The company has a 50 day moving average of $3.46 and a 200 day moving average of $3.48.

Kiora Pharmaceuticals (NASDAQ:KPRX) last posted its quarterly earnings results on Tuesday, March 25th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.40). The firm had revenue of $0.75 million during the quarter, compared to analysts’ expectations of $0.75 million. Research analysts forecast that Kiora Pharmaceuticals will post 1.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kiora Pharmaceuticals

An institutional investor recently raised its position in Kiora Pharmaceuticals stock. ADAR1 Capital Management LLC boosted its position in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) by 1.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 200,221 shares of the company’s stock after acquiring an additional 3,670 shares during the period. ADAR1 Capital Management LLC owned 6.67% of Kiora Pharmaceuticals worth $661,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 76.97% of the company’s stock.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.